Loading
Led the first trials of BRAF inhibition in melanoma and chairs the NCI-MATCH precision medicine trial.
Keith T. Flaherty is Director of Clinical Research at the Mass General Cancer Center. He is a melanoma oncologist known for leading the first trials of BRAF inhibition, as first author of the 2010 vemurafenib study, and for the dabrafenib plus trametinib combination work that followed. His selected papers report inhibition of mutated, activated BRAF in metastatic melanoma and combined BRAF and MEK inhibition in BRAF V600-mutant melanoma. He co-chairs the NCI-MATCH precision medicine trial and continues to work on small-molecule kinase inhibitors.
| Title | Journal | Year |
|---|---|---|
| Inhibition of mutated, activated BRAF in metastatic melanoma | New England Journal of Medicine | 2010 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | New England Journal of Medicine | 2012 |
Shares COMBI-d, BRAF V600-mutant melanoma, BRAF, Melanoma.
Shares Dabrafenib + trametinib, BRAF, Melanoma.
Shares Vemurafenib, BRAF, Melanoma.
Shares COMBI-d, BRAF V600-mutant melanoma.
Shares NCI-MATCH (EAY131), Master protocol (platform, basket and umbrella trials), Small-molecule kinase inhibitors.
Shares Dabrafenib + trametinib, BRAF V600-mutant melanoma, BRAF, Melanoma.
Shares Vemurafenib, BRAF V600-mutant melanoma, BRAF, Melanoma.
Shares Dabrafenib + trametinib, BRAF, Melanoma.